biropepimut-S (GL-0817) / Gliknik, University of Pennsylvania - LARVOL DELTA

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Gliknik Inc. | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MAGEA3

Gliknik Inc. Raises $11.5 Million in Series C Financing (Businesswire) - “Gliknik…announced that it has successfully completed an $11.5 million Series C Preferred Stock financing…Funding will help advance Gliknik clinical and pre-clinical programs, including: A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion. Clinicians are assessing two-year endpoints in the prevention-of-recurrence of high-risk squamous cell oral cavity cancer.”

Financing • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - P2; N=80; Active, not recruiting; Sponsor: Gliknik Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed